Head of the Immunology Service
Two preclinical studies published in the journal Science have introduced new bioengineered modifications to CAR-T cells in an attempt to make them more potent and safer in their anti-tumour action. These variations allow their activity to be enhanced only in the vicinity of the tumour or their actions to be regulated on demand.
A pioneering phase 1 clinical trial has tested a type of cancer immunotherapy. Researchers have modified patients' own T-lymphocyte receptors using the CRISPR tool to direct them against specific targets on their own tumours. The results are published in the journal Nature.
US researchers have designed an intranasal vaccination device that is capable of delivering immunising proteins through the mucosal surface. The research, published in Science Translational Medicine, shows that strong antibody responses against viruses such as HIV and SARS-CoV-2 have been achieved in mice and non-human primates.
The director of the Vaccine Strategy of the European Medicines Agency (EMA), Marco Cavaleri, told a press conference on 11 January that "it is not sustainable in the long term to continue giving booster doses every three or four months [to the general population]". Spanish immunologists agree that this is not the right thing to do. In these reactions they explain why.
The first solid work on the ability of vaccines to stop infection with the omicron variant, which has just been published, reinforces the need for a third dose. Experts recall, however, that the aim of vaccines was never to stop infection, but to prevent severe disease. We summarize what is known so far about it.
In the last few days, data, preprints, press releases and even graphs have started to arrive via social media showing how neutralising antibodies against the omicron variant behave. These studies are preliminary and we will have to wait and see how these lab data translate into the real world.
The European Medicines Agency issued its recommendations yesterday afternoon regarding the administration of a third dose of the Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) vaccines. These are the reactions of several experts on the matter.